{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:35:42Z","timestamp":1788813342722,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"ITK Diagnostics"},{"name":"ZEUS Scientific"},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s10096-021-04372-6","type":"journal-article","created":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:03:45Z","timestamp":1637539425000},"page":"387-393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Diagnostic performance of the ZEUS Borrelia VlsE1\/pepC10 assay in European LB patients: a case\u2013control study"],"prefix":"10.1007","volume":"41","author":[{"given":"M. E.","family":"Baarsma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vrijlandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ursinus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. L.","family":"Zaaijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jurriaans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. P.","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. W.","family":"Hovius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"issue":"12","key":"4372_CR1","doi-asserted-by":"publisher","first-page":"e0168613","DOI":"10.1371\/journal.pone.0168613","volume":"11","author":"LA Waddell","year":"2016","unstructured":"Waddell LA, Greig J, Mascarenhas M, Harding S, Lindsay R, Ogden N (2016) The accuracy of diagnostic tests for lyme disease in humans, a systematic review and meta-analysis of North American Research. PLoS One 11(12):e0168613","journal-title":"PLoS One"},{"key":"4372_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s12879-016-1468-4","volume":"16","author":"MMG Leeflang","year":"2016","unstructured":"Leeflang MMG, Ang CW, Berkhout J, Bijlmer HA, Van Bortel W, Brandenburg AH et al (2016) The diagnostic accuracy of serological tests for Lyme borreliosis in Europe: a systematic review and meta-analysis. BMC Infect Dis 16:140","journal-title":"BMC Infect Dis"},{"issue":"10","key":"4372_CR3","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.4049\/jimmunol.163.10.5566","volume":"163","author":"FT Liang","year":"1999","unstructured":"Liang FT, Alvarez AL, Gu Y, Nowling JM, Ramamoorthy R, Philipp MT (1999) An immunodominant conserved region within the variable domain of VlsE, the variable surface antigen of Borrelia burgdorferi. J Immunol 163(10):5566\u20135573","journal-title":"J Immunol"},{"issue":"11","key":"4372_CR4","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s10096-020-03946-0","volume":"39","author":"ME Baarsma","year":"2020","unstructured":"Baarsma ME, Schellekens J, Meijer BC, Brandenburg AH, Souilljee T, Hofhuis A et al (2020) Diagnostic parameters of modified two-tier testing in European patients with early Lyme disease. Eur J Clin Microbiol Infect Dis 39(11):2143\u20132152","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"4372_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/cid\/cir464","volume":"53","author":"JA Branda","year":"2011","unstructured":"Branda JA, Linskey K, Kim YA, Steere AC, Ferraro MJ (2011) Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis 53(6):541\u2013547","journal-title":"Clin Infect Dis"},{"issue":"8","key":"4372_CR6","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/cid\/cix043","volume":"64","author":"JA Branda","year":"2017","unstructured":"Branda JA, Strle K, Nigrovic LE, Lantos PM, Lepore TJ, Damle NS et al (2017) Evaluation of modified 2-tiered serodiagnostic testing algorithms for early Lyme disease. Clin Infect Dis 64(8):1074\u20131080","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4372_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa1215","volume":"72","author":"PM Lantos","year":"2021","unstructured":"Lantos PM, Rumbaugh J, Bockenstedt LK, Falck-Ytter YT, Aguero-Rosenfeld ME, Auwaerter PG et al (2021) Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis and treatment of Lyme disease. Clin Infect Dis 72(1):e1\u2013e48","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4372_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.diagmicrobio.2012.09.003","volume":"75","author":"GP Wormser","year":"2013","unstructured":"Wormser GP, Schriefer M, Aguero-Rosenfeld ME, Levin A, Steere AC, Nadelman RB et al (2013) Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis 75(1):9\u201315","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"12","key":"4372_CR9","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1128\/JCM.36.12.3474-3479.1998","volume":"36","author":"MJ Mathiesen","year":"1998","unstructured":"Mathiesen MJ, Christiansen M, Hansen K, Holm A, Asbrink E, Theisen M (1998) Peptide-based OspC enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis. J Clin Microbiol 36(12):3474\u20133479","journal-title":"J Clin Microbiol"},{"issue":"5","key":"4372_CR10","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1128\/CVI.00409-10","volume":"18","author":"RB Porwancher","year":"2011","unstructured":"Porwancher RB, Hagerty CG, Fan J, Landsberg L, Johnson BJ, Kopnitsky M et al (2011) Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10-IgM antibodies: improving test performance through bioinformatics. Clin Vaccine Immunol 18(5):851\u2013859","journal-title":"Clin Vaccine Immunol"},{"issue":"8","key":"4372_CR11","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1086\/374395","volume":"187","author":"RM Bacon","year":"2003","unstructured":"Bacon RM, Biggerstaff BJ, Schriefer ME, Gilmore RD Jr, Philipp MT, Steere AC et al (2003) Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis 187(8):1187\u20131199","journal-title":"J Infect Dis"},{"issue":"8","key":"4372_CR12","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1373\/clinchem.2005.048595","volume":"51","author":"AW Rutjes","year":"2005","unstructured":"Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM (2005) Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem 51(8):1335\u20131341","journal-title":"Clin Chem"},{"key":"4372_CR13","doi-asserted-by":"crossref","unstructured":"Baarsma ME, Ursinus J, Zaaijer HL, Kuiper H, Hovius JW (2021) Diagnostic performance of the novel BioPlex Lyme serological assays in European patients with Lyme disease. J Clin Microbiol 59(7):e0320520.","DOI":"10.1128\/JCM.03205-20"},{"issue":"1","key":"4372_CR14","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/j.1469-0691.2010.03175.x","volume":"17","author":"G Stanek","year":"2011","unstructured":"Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A et al (2011) Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 17(1):69\u201379","journal-title":"Clin Microbiol Infect"},{"key":"4372_CR15","unstructured":"Borrelia VlsE1\/pepC10 IgG\/IgM Test System: ZEUS Scientific. Available from:\u00a0https:\/\/www.zeusscientific.com\/products\/zeus-elisa-test-systems\/zeus-elisa-borrelia-vlse1-pepc10-igg-igm-test-system. Accessed 3 Sept 2021"},{"key":"4372_CR16","unstructured":"FDA clears new indications for existing Lyme disease tests that may help streamline diagnoses [press release]. Food and Drug Administration, 29 July, 2019.\u00a0Available from:https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-new-indications-existing-lyme-disease-testsmay-help-streamline-diagnoses.\u00a0Accessed 1 Sept 2021"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04372-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-021-04372-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04372-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,15]],"date-time":"2023-01-15T23:03:49Z","timestamp":1673823829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-021-04372-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4372"],"URL":"https:\/\/doi.org\/10.1007\/s10096-021-04372-6","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]},"assertion":[{"value":"6 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was submitted to the Medical Ethics Committee of Amsterdam UMC, which found it to be outside the scope of the Dutch Medical Research Involving Human Subjects Act (MEC decision W20_455).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"As this study used only de-identified leftover patient materials, informed consent from patients was not required. Healthy blood donors consented specifically to their materials being used for scientific purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"None of the authors have received any personal financial compensation from ZEUS Scientific or any of the other assays\u2019 manufacturers. MEB and JWH have in the past collaborated with Bio-Rad Laboratories (Hercules, CA, USA), QIAGEN (Germantown, MD, USA), Oxford Immunotec (Oxford, UK), Invitalabs (Neuss, Germany) and AID (Strassberg, Germany) on unrelated projects on LB diagnostics. They have not received any personal financial compensation from any of the aforementioned companies. MEB, APvD and JWH collaborate with Pfizer (New York City, NY, USA) on unrelated projects on LD. They have not received any personal financial compensation from Pfizer or any of the other companies for these projects. The other authors report no potential conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}